Clozapine + Aripiprazole Combination in Very early-onset Ressistant Schizophrenia. A case study

Downloads

Published

2021-09-30

How to Cite

Osorio, Ángela, Antúnez María, B., Hernando Segura, R., & Gordo Seco, R. (2021). Clozapine + Aripiprazole Combination in Very early-onset Ressistant Schizophrenia. A case study. Revista De Psiquiatría Infanto-Juvenil, 38(3), 33–38. https://doi.org/10.31766/revpsij.v38n3a5

Issue

Vol. 38 No. 3 (2021): July-September

Section

Case reports
Crossref
Scopus
Google Scholar
Europe PMC

Authors

  • Ángela Osorio Licenciada Especialista de Área. Unidad de Salud Mental Infanto-Juvenil, Complejo Asistencial Universitario de Burgos, https://orcid.org/0000-0001-8729-8978
  • B. Antúnez María Licenciada Especialista de Área. Unidad de Hospitalización Psiquiátrica Infanto-Juvenil. Hospital Universitario de Donostia
  • R. Hernando Segura Licenciada Especialista de Área. Unidad de Salud Mental Infanto-Juvenil, Complejo Asistencial Universitario de Burgos
  • R. Gordo Seco Licenciada Especialista de Área. Unidad de Salud Mental Infanto-Juvenil, Complejo Asistencial Universitario de Burgos https://orcid.org/0000-0002-1106-1920

DOI:

https://doi.org/10.31766/revpsij.v38n3a5

Keywords:

Schizophrenia, Childhood, Clozapine, Aripiprazole, Drug Combination

Abstract

Early-Onset Schizophrenia is a rare but very serious condition, which requires the early establishment of an effective treatment. Clozapine is the standard in the treatment of refractory psychosis and its efficacy in children and adolescents is similar to that in adults, although this population is at higher risk of potentially serious adverse effects that interfere in their functioning and life quality. A strategy to overcome these drawbacks commonly used in clinical practice is antipsychotics combination, based on the fact that reducing the dose of drugs compared to monotherapy, reduces the adverse effects that occur at higher doses. We present the case of a 13-year-old male patient, diagnosed with Very Early-Onset Paranoid Schizophrenia, resistant to treatment, in which the combination of Clozapine + Aripiprazole was used with good results in terms of efficacy and tolerance. The patient also presented obsessive-compulsive symptoms that were linked to clozapine, which remitted after adding Aripiprazole to the treatment.

Downloads

Download data is not yet available.

References

Rey JM (editor). IACAPAP e-Textbook of Child and Adolescent Mental Health. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions 2015.

Stahl S. Psicofarmacología Esencial de Stahl. Guía del prescriptor. Sexta ed. Toledo: Grupo Aula Médica; 2018.

Sánchez-Araña Moreno T, González Moreno JM, Rueda Villar T, Ruiz Doblado S. Potenciación de clozapina con aripiprazol en esquizofrenia resistente: informe de casos. Psiquiatría Biológica. 2007; 14(2): p. 77-80. https://doi.org/10.1016/S1134-5934(07)73264-5 DOI: https://doi.org/10.1016/S1134-5934(07)73264-5

Sporn A, Vermani A, Greenstein D, Bobb A, Spencer E, Clasen L, et al.. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007; 46(10): p. 1349-56. https://doi.org/10.1097/chi.0b013e31812eed10 DOI: https://doi.org/10.1097/chi.0b013e31812eed10

Kranzler HN, Cohen SD. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatr Clin N Am. 2013; 22(4): 727-44. https://doi.org/10.1016/j.chc.2013.06.002 DOI: https://doi.org/10.1016/j.chc.2013.06.002

Boehme K V, Durán L E. Experiencia clínica con el antipsicótico clozapina en niños y adolescentes menores de 18 años en Chile. Revista Chilena de Neuropsiquiatría [Internet]. 2012; 50(2): 85-99. https://www.redalyc.org/articulo.oa?id=331527729002 DOI: https://doi.org/10.4067/S0717-92272012000200002

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M et al. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza. Psiquiatría Biológica. 2011; 18: 55-67. https://doi.org/10.1016/j.psiq.2011.06.001 DOI: https://doi.org/10.1016/j.psiq.2011.06.001

Englisch S, Esslinger C, Inta D, Weinbrenner A, Peus V, Gutschalk A et al. Clozapine-Induced Obsessive-Compulsive Syndromes Improve in Combination With Aripiprazole. Clinical Neuropharmacology. 2009; 32: 227-229. https://doi.org/10.1097/WNF.0b013e31819cc8e6 DOI: https://doi.org/10.1097/WNF.0b013e31819cc8e6

Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019; 76: 499-507. https://doi.org/10.1001/jamapsychiatry.2018.4320 DOI: https://doi.org/10.1001/jamapsychiatry.2018.4320

Sohn M, Burgess M, Bazzi M. Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings. Pharmacy (Basel). 2017; 5: 64. https://doi.org/10.3390/pharmacy5040064 DOI: https://doi.org/10.3390/pharmacy5040064

Bachmann CJ, Lehr D, Theisen FM, Preiss M. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry. 2009; 42: 153-7. https://doi.org/10.1055/s-0029-1202266. DOI: https://doi.org/10.1055/s-0029-1202266

Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011; 133: 54-62. https://doi.org/10.1016/j.schres.2011.09.016. DOI: https://doi.org/10.1016/j.schres.2011.09.016

Mitchel MW, Moreno-De-Luca D, Myers SM, et al. 17q12 Recurrent Deletion Syndrome. 2016 Dec 8 [Updated 2020 Oct 15]. En: Adam MP, Ardinger HH, Pagon RA, et al., editores. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. https://www.ncbi.nlm.nih.gov/books/NBK401562/